Lumira Ventures

Puzzle Medical Devices Inc., founded in 2018 and based in Montreal, Canada, focuses on developing innovative heart pump technologies for treating advanced heart failure. The company's flagship product, the ModulHeart, is a modular percutaneous heart pump designed to reduce cardiac afterload and enhance renal perfusion in patients who are not candidates for heart transplant or surgical mechanical circulatory support. Its unique design allows for multiple pumps to be anchored in parallel within the descending aorta, facilitating hemodynamic support while minimizing risks associated with traditional procedures, such as bleeding and stroke. The ModulHeart aims to improve patient outcomes by providing sustained symptom relief, reducing hospital readmissions, and enhancing overall quality of life. Puzzle Medical has made significant progress, including completing its first-in-human study with positive results in cardiac and kidney function, receiving FDA Breakthrough Device Designation, and establishing a strong network of Key Opinion Leaders in the field.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Sound Blade Medical is an early stage medical device startup that revolutionizes healthcare by enhancing endoscopic, image-guided histotripsy.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

KisoJi Biotechnology is an early-stage biotechnology company focused on developing innovative antibodies for cancer treatment. The company utilizes a unique platform that enables the identification and visualization of a comprehensive range of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's approach includes the use of multi-species single-domain antibody transgenic mice and AI-driven antibody fingerprinting to match specific epitopes on targets effectively. This technology supports the development of multi-specific antibodies that are robust and easily manufacturable, with the potential to enhance therapeutic outcomes for cancer and other diseases.

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices. It enhances the diagnosis and treatment of cardiovascular diseases and primarily operates in the diagnostic equipment, medical business/industry. The Waltham, Massachusetts based company was founded in 2017.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.

Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significant improvement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program. Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, established in 2016. The company focuses on developing and commercializing an injectable hydrogel technology designed to enhance drug delivery for various medical applications. This innovative platform aims to improve patient outcomes in areas such as post-surgical pain management, cancer treatment, and other challenging therapeutic targets. AmacaThera's technology features a fast-gelling material that transitions from a liquid to a gel under force, combining hyaluronan and methylcellulose. This unique formulation allows for localized and sustained drug delivery, ultimately assisting healthcare providers in effectively managing patients' pain following surgery.

Specific Biologics is focused on advancing gene-editing technologies aimed at treating genetic diseases at the cellular level. The company's core innovation is a platform technology that features a dual-cleaving nuclease, which can be safely delivered to target cells. This technology leverages the body’s inherent DNA repair mechanisms, allowing for enhanced repair or precise deletions of genetic material. By utilizing these natural pathways, Specific Biologics aims to offer effective therapeutic solutions for a range of genetic disorders.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

PIC Therapeutics, Inc. is a biotechnology company dedicated to innovating cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and based in Boston, Massachusetts, the company focuses on developing therapeutics that target the "master switch" of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This precision-based approach has the potential to simultaneously address multiple oncogenic drivers, thereby improving patient outcomes and advancing a new generation of cancer treatments.

Damona Pharmaceuticals is a pre-clinical pharmaceutical company treats and prevents cognitive deficits in a variety of brain disorders and during aging.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for primary immune deficiencies and cancer. The company's lead candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. It is in Phase III for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and in Phase Ib for severe congenital neutropenia and Waldenström macroglobulinemia. Additionally, mavorixafor is being explored in Phase IIa trials for clear cell renal cell carcinoma. X4 Pharmaceuticals is also advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 for primary immune deficiencies. The company has partnered with Abbisko Therapeutics Co., Ltd. to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. and rebranded in March 2019.

Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Specific Biologics is focused on advancing gene-editing technologies aimed at treating genetic diseases at the cellular level. The company's core innovation is a platform technology that features a dual-cleaving nuclease, which can be safely delivered to target cells. This technology leverages the body’s inherent DNA repair mechanisms, allowing for enhanced repair or precise deletions of genetic material. By utilizing these natural pathways, Specific Biologics aims to offer effective therapeutic solutions for a range of genetic disorders.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapies for Long QT Syndrome and various arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, atrial fibrillation, and treatment-resistant cancers. Thryv Therapeutics is dedicated to creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to reduce the risk of sudden cardiac death and enhance the quality of life for affected patients. Through its targeted therapeutic development, the company seeks to provide effective solutions for serious cardiovascular and oncological conditions.

BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, focused on developing innovative therapies that restore protein homeostasis through targeted protein degradation. The company specializes in Protein Homeostatic Modulators and small molecule targeted protein degraders (TPDs), which utilize a unique mechanism involving molecular glues to regulate protein levels within the body. Their proprietary PRODEGY platform is built on a library of Cereblon binders, enabling the design of bifunctional and hybrid degraders aimed at treating various diseases, particularly cancer. BioTheryX's lead candidate, BTX-A51, is an oral small molecule and multi-kinase inhibitor targeting specific leukemic stem cells and oncogenic transcription factors. Established in 2007, BioTheryX aims to address significant unmet medical needs by leveraging its expertise in protein modulation and degradation.

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, established in 2016. The company focuses on developing and commercializing an injectable hydrogel technology designed to enhance drug delivery for various medical applications. This innovative platform aims to improve patient outcomes in areas such as post-surgical pain management, cancer treatment, and other challenging therapeutic targets. AmacaThera's technology features a fast-gelling material that transitions from a liquid to a gel under force, combining hyaluronan and methylcellulose. This unique formulation allows for localized and sustained drug delivery, ultimately assisting healthcare providers in effectively managing patients' pain following surgery.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing targeted therapeutics for cancer treatment. Founded in 2010, the company specializes in innovative cancer therapies, with its leading product, Tegavivint, being a selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a significant role in processes such as cell proliferation and immune evasion. Tegavivint has shown pre-clinical efficacy in various cancer models, including desmoid tumors, acute myeloid leukemia, osteosarcoma, and several solid tumors. Iterion is currently conducting a Phase I clinical study for Tegavivint in patients with desmoid tumors across multiple clinical sites in the United States and Canada, aiming to provide effective treatment options for patients with challenging cancers.

Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Based in Toronto, Canada, the company utilizes a proprietary platform for induced pluripotent stem cell (iPSC) technology that allows for precision control of Notch signaling, which is essential for T cell development. This innovative approach addresses critical limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. Notch Therapeutics aims to provide targeted treatments for conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, facilitating advancements in the treatment of complex disease systems. Established in 2018, the company is positioned at the forefront of next-generation cancer therapies.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significant improvement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program. Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

IMV Inc. is a clinical-stage biopharmaceutical company based in Dartmouth, Canada, focused on developing innovative cancer immunotherapies and vaccines for infectious diseases. The company utilizes its patented DepoVax platform to enhance immune responses, allowing for controlled and prolonged exposure of antigens. Its lead candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in multiple Phase 1 and 1b trials for late-stage ovarian cancer and relapsed/refractory diffuse large B cell lymphoma (DLBCL). IMV is currently conducting Phase 2 trials for DPX-Survivac across several cancer indications and exploring its use in combination with Merck's Keytruda. Additionally, IMV is developing a DPX-based vaccine candidate against COVID-19 and a vaccine targeting the respiratory syncytial virus. The company also has a diverse pipeline of vaccine candidates for various infectious diseases, including malaria and anthrax, and maintains partnerships in the animal health sector.

IMV Inc. is a clinical-stage biopharmaceutical company based in Dartmouth, Canada, focused on developing innovative cancer immunotherapies and vaccines for infectious diseases. The company utilizes its patented DepoVax platform to enhance immune responses, allowing for controlled and prolonged exposure of antigens. Its lead candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in multiple Phase 1 and 1b trials for late-stage ovarian cancer and relapsed/refractory diffuse large B cell lymphoma (DLBCL). IMV is currently conducting Phase 2 trials for DPX-Survivac across several cancer indications and exploring its use in combination with Merck's Keytruda. Additionally, IMV is developing a DPX-based vaccine candidate against COVID-19 and a vaccine targeting the respiratory syncytial virus. The company also has a diverse pipeline of vaccine candidates for various infectious diseases, including malaria and anthrax, and maintains partnerships in the animal health sector.

Bright Angel Therapeutics focuses on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the effectiveness of existing antifungal therapies and eliminate drug resistance by specifically targeting the stress responses that fungi rely on for survival and virulence. By addressing these critical factors, Bright Angel Therapeutics seeks to mitigate the common occurrence of clinical resistance, which is a major contributor to the significant morbidity and mortality associated with various fungal infections. Through its research and development efforts, the company endeavors to improve patient outcomes in the face of challenging fungal pathogens.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, established in 2016. The company focuses on developing and commercializing an injectable hydrogel technology designed to enhance drug delivery for various medical applications. This innovative platform aims to improve patient outcomes in areas such as post-surgical pain management, cancer treatment, and other challenging therapeutic targets. AmacaThera's technology features a fast-gelling material that transitions from a liquid to a gel under force, combining hyaluronan and methylcellulose. This unique formulation allows for localized and sustained drug delivery, ultimately assisting healthcare providers in effectively managing patients' pain following surgery.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Bardy Diagnostics is a developer of a cardiac monitor and arrhythmia detection device. The company has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy. It is also designed to be comfortable for women to wear, with its narrow, hourglass shape. Bardy Diagnostics uses his expertise to develop cardiac monitoring solutions that help physicians obtain more accurate information about actionable events in the hopes of saving lives. The company's mission is to improve clinical management and outcomes for patients and their physicians by employing innovative P-wave centric ECG detection into patient-friendly technologies that result in greater patient compliance and more confident physician diagnoses. Bardy Diagnostics was founded in 2013 and is headquartered in Seattle, Washington, USA.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

Exact Imaging specializes in high-resolution micro-ultrasound systems aimed at improving real-time imaging and guided biopsies in the urological sector, particularly for prostate cancer. The company's flagship product, the ExactVu system, operates at 29 MHz, providing exceptional resolution that allows for the visualization and targeting of suspicious regions. In addition to enabling precise systematic biopsies, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI to enhance prostate imaging and biopsy accuracy. Founded in 2003 and headquartered in Markham, Canada, the company was previously known as Imagistx, Inc. before rebranding in 2015.

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

Gladius Pharmaceuticals Inc. is a biotechnology company based in Montréal that focuses on developing innovative antibiotics to combat life-threatening, multi-drug-resistant bacterial infections. The firm is dedicated to creating novel drug candidates that offer broad-spectrum efficacy against gram-negative pathogens. Its antibiotics are designed to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby enabling healthcare providers to treat bacterial infections more effectively.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

KisoJi Biotechnology is an early-stage biotechnology company focused on developing innovative antibodies for cancer treatment. The company utilizes a unique platform that enables the identification and visualization of a comprehensive range of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's approach includes the use of multi-species single-domain antibody transgenic mice and AI-driven antibody fingerprinting to match specific epitopes on targets effectively. This technology supports the development of multi-specific antibodies that are robust and easily manufacturable, with the potential to enhance therapeutic outcomes for cancer and other diseases.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

KalGene Pharmaceuticals Inc. is a privately held company based in Candiac, Canada, that specializes in the development of precision medicine for Alzheimer’s disease. Founded in 2006, KalGene collaborates with prominent clinician-scientists and academic institutions across North America and Europe. The company's focus is on creating targeted therapeutics and companion diagnostics aimed at enhancing clinical outcomes and survival rates through personalized medicine. By utilizing individual biological signatures, KalGene's approach seeks to predict patient responses to specific therapies, enabling healthcare providers to tailor treatments to meet the unique needs of each patient.

Exact Imaging specializes in high-resolution micro-ultrasound systems aimed at improving real-time imaging and guided biopsies in the urological sector, particularly for prostate cancer. The company's flagship product, the ExactVu system, operates at 29 MHz, providing exceptional resolution that allows for the visualization and targeting of suspicious regions. In addition to enabling precise systematic biopsies, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI to enhance prostate imaging and biopsy accuracy. Founded in 2003 and headquartered in Markham, Canada, the company was previously known as Imagistx, Inc. before rebranding in 2015.

KisoJi Biotechnology is an early-stage biotechnology company focused on developing innovative antibodies for cancer treatment. The company utilizes a unique platform that enables the identification and visualization of a comprehensive range of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's approach includes the use of multi-species single-domain antibody transgenic mice and AI-driven antibody fingerprinting to match specific epitopes on targets effectively. This technology supports the development of multi-specific antibodies that are robust and easily manufacturable, with the potential to enhance therapeutic outcomes for cancer and other diseases.

Exact Imaging specializes in high-resolution micro-ultrasound systems aimed at improving real-time imaging and guided biopsies in the urological sector, particularly for prostate cancer. The company's flagship product, the ExactVu system, operates at 29 MHz, providing exceptional resolution that allows for the visualization and targeting of suspicious regions. In addition to enabling precise systematic biopsies, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI to enhance prostate imaging and biopsy accuracy. Founded in 2003 and headquartered in Markham, Canada, the company was previously known as Imagistx, Inc. before rebranding in 2015.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for inflammatory diseases, cancer, and autoimmune disorders. Established in 2007 and headquartered in Atlanta, Georgia, the company is engaged in developing drug compounds that manipulate immune cell migration and activation. One of its key products, CTX-4430, is a small-molecule drug designed to inhibit the enzyme Leukotriene A4 hydrolase in immune cells, targeting conditions such as cystic fibrosis and moderately severe acne. Celtaxsys aims to provide innovative treatments that address the protective mechanisms of certain tumors, thereby enhancing the immune response against cancer and managing serious inflammatory conditions.

KalGene Pharmaceuticals Inc. is a privately held company based in Candiac, Canada, that specializes in the development of precision medicine for Alzheimer’s disease. Founded in 2006, KalGene collaborates with prominent clinician-scientists and academic institutions across North America and Europe. The company's focus is on creating targeted therapeutics and companion diagnostics aimed at enhancing clinical outcomes and survival rates through personalized medicine. By utilizing individual biological signatures, KalGene's approach seeks to predict patient responses to specific therapies, enabling healthcare providers to tailor treatments to meet the unique needs of each patient.

Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company’s lead investigational drug is Staccato® alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures. Staccato alprazolam in a Phase 2a proof of concept study demonstrated reduction of seizure in a photosensitivity model. The product will proceed into an advanced clinical setting leveraging a 505(b)(2) regulatory pathway.

Stellar Biotechnologies, previously an independent biotechnology company based in Port Hueneme, California, specialized in the sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein. KLH is utilized as a carrier molecule in therapeutic vaccine development for a range of diseases, including cancer, immune disorders, and Alzheimer's, and is also employed in assessing immune system function. The company provided KLH protein in various grades and formulations for drug development and research, including KLH-based in vitro diagnostic kits for research and preclinical applications. Its clientele consisted of biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. In June 2019, Stellar Biotechnologies was acquired by Edesa Biotech Inc., which focuses on innovative treatments for inflammatory and immune-related diseases.

Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. The initial focus is on developing novel, safe and potent alternatives to steroids for Allergic Contact Dermatitis, Hemorrhoids, and Anal Fissures. Edesa Biotech’s lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.

Exact Imaging specializes in high-resolution micro-ultrasound systems aimed at improving real-time imaging and guided biopsies in the urological sector, particularly for prostate cancer. The company's flagship product, the ExactVu system, operates at 29 MHz, providing exceptional resolution that allows for the visualization and targeting of suspicious regions. In addition to enabling precise systematic biopsies, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI to enhance prostate imaging and biopsy accuracy. Founded in 2003 and headquartered in Markham, Canada, the company was previously known as Imagistx, Inc. before rebranding in 2015.

KisoJi Biotechnology is an early-stage biotechnology company focused on developing innovative antibodies for cancer treatment. The company utilizes a unique platform that enables the identification and visualization of a comprehensive range of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's approach includes the use of multi-species single-domain antibody transgenic mice and AI-driven antibody fingerprinting to match specific epitopes on targets effectively. This technology supports the development of multi-specific antibodies that are robust and easily manufacturable, with the potential to enhance therapeutic outcomes for cancer and other diseases.

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

Opsens Inc. specializes in the development, manufacturing, and sale of fiber optic sensors for various applications, including interventional cardiology, fractional flow reserve (FFR), and industrial uses. The company operates through two segments: Medical and Industrial. The Medical segment focuses on physiological measurements, particularly in coronary artery disease, offering products such as the OptoWire, an advanced optical-based pressure guidewire designed to improve clinical outcomes, and a range of miniature optical sensors for pressure and temperature measurement that can be integrated into other medical devices. The Industrial segment provides fiber optic sensing solutions for various industries, including life sciences, energy, defense, aerospace, and civil engineering. Opsens markets its products through a direct sales force and distributors in regions such as the United States, Japan, and Canada, with its headquarters located in Québec, Canada.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics primarily for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various cancers such as biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials targeting advanced or metastatic HER2-expressing cancers. Zymeworks utilizes a combination of proprietary molecular modeling, simulation software, and high-performance computing to optimize therapeutic antibodies and other protein-based treatments. The company has established strategic partnerships with several leading pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Additionally, Zymeworks is advancing a preclinical pipeline that includes candidates for oncology and other therapeutic areas, reflecting its commitment to addressing unmet medical needs.

This national mobile wellness rewards initiative harnesses the public’s affinity for popular loyalty points, the convenience of smart phone technology and Canadians’ natural desire to lead healthier lives. It is this unique combination that results in such a powerful “nudge” platform – in support of a healthier

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

First Aid Shot Therapy offers a market segment defined as clinical beverages designed to address acute or chronic clinical needs. It offers a range of easy-to-swallow, single-dose products that provide fast-acting relief for most common everyday symptoms; hangover, pain, sleep, cold, allergy, and heartburn. The company was founded in 2010 and is headquartered in Burlingame, California.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

Gladius Pharmaceuticals Inc. is a biotechnology company based in Montréal that focuses on developing innovative antibiotics to combat life-threatening, multi-drug-resistant bacterial infections. The firm is dedicated to creating novel drug candidates that offer broad-spectrum efficacy against gram-negative pathogens. Its antibiotics are designed to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby enabling healthcare providers to treat bacterial infections more effectively.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for inflammatory diseases, cancer, and autoimmune disorders. Established in 2007 and headquartered in Atlanta, Georgia, the company is engaged in developing drug compounds that manipulate immune cell migration and activation. One of its key products, CTX-4430, is a small-molecule drug designed to inhibit the enzyme Leukotriene A4 hydrolase in immune cells, targeting conditions such as cystic fibrosis and moderately severe acne. Celtaxsys aims to provide innovative treatments that address the protective mechanisms of certain tumors, thereby enhancing the immune response against cancer and managing serious inflammatory conditions.

Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).

Vascular Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with type 1 and type 2 diabetes, specifically targeting complications such as diabetic nephropathy. Founded in 2005 and based in North Carolina, the company is advancing its lead candidate, VPI-2690B, a subcutaneously administered monoclonal antibody designed to respond to hyperglycemia. This innovative treatment aims to bind to a specific molecular target within the αVβ3 receptor, potentially offering patients a means to mitigate the serious complications associated with diabetes. Vascular Pharmaceuticals operates at the intersection of biotechnology, medicine, and healthcare, contributing to the ongoing efforts to improve outcomes for those affected by diabetes.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

OsteoQC Inc is a company that develops new drugs and therapies for the treatment of bone-related diseases.

Osteopathy Quebec is a life science company that uses manual methods with the goal of restoring the functionality of all the body's systems and structures to enhance its ability for self-regulation. Its technicality is based on a detailed understanding of health sciences and interactions particular to the organism's equilibrium homeostasis.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.

Corvia Medical is a medical device company based in Andover, Massachusetts, established in 2009. The company specializes in developing innovative solutions for heart failure, particularly through its InterAtrial Shunt Device (IASD). This transcatheter device is designed to address diastolic heart failure, also known as heart failure with preserved ejection fraction. The IASD works by creating a small opening between the left and right atria, which helps to lower blood pressure in the left atrium and lungs. This reduction in pressure aims to alleviate symptoms and slow the progression of heart failure, allowing patients to maintain a healthier lifestyle and reduce their risk of severe heart-related complications.

Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, dedicated to developing non-fusion motion preservation systems for treating degenerative diseases of the spine. Founded in 2003, the company offers two primary products: the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical characteristics of natural intervertebral discs. These innovations provide options for artificial disc replacement in the cervical and lumbar regions. Spinal Kinetics collaborates with spine surgeons to ensure that its products meet clinical needs and are sold through a network of distributors across various countries, including Australia, Germany, the United Kingdom, and the United Arab Emirates. The company operates as a subsidiary of Orthofix Medical Inc.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with high unmet medical needs. The company is engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia's primary market for its products is the United States, with ongoing efforts to address the needs of targeted patient populations suffering from these conditions.

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to discovering and developing personalized therapies for unmet medical needs in oncology. The company focuses on small molecule cancer therapeutics, with a pipeline that includes APTO-253, currently in a Phase 1b trial for patients with relapsed/refractory blood cancers such as acute myeloid leukemia and high-risk myelodysplastic syndrome. Additionally, Aptose is collaborating with CrystalGenomics, Inc. on CG026806, which is in a Phase 1a/b trial for relapsed/refractory acute myeloid leukemia and various B-cell malignancies. Another partnership with OHM Oncology involves the development and commercialization of APL-581 for the treatment of hematologic malignancies. Founded in 1986 and headquartered in Toronto, Canada, Aptose Biosciences was previously known as Lorus Therapeutics Inc. and changed its name in August 2014.

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with high unmet medical needs. The company is engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia's primary market for its products is the United States, with ongoing efforts to address the needs of targeted patient populations suffering from these conditions.

Vendorlink.ca is a provider of web-based vendor management solutions.

Corvia Medical is a medical device company based in Andover, Massachusetts, established in 2009. The company specializes in developing innovative solutions for heart failure, particularly through its InterAtrial Shunt Device (IASD). This transcatheter device is designed to address diastolic heart failure, also known as heart failure with preserved ejection fraction. The IASD works by creating a small opening between the left and right atria, which helps to lower blood pressure in the left atrium and lungs. This reduction in pressure aims to alleviate symptoms and slow the progression of heart failure, allowing patients to maintain a healthier lifestyle and reduce their risk of severe heart-related complications.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.